KCTBASE

Carboplatin을 포함한 항암제 투여환자에서 유발된 오심, 구토에 대한 palonosetron과 ramosetron의 항구토효과 비교
A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs

병원약사회지 2010년 27권 4호 p.392 ~ p.399

고영주(Ko Young-Joo) - 가톨릭대학교 서울성모병원 약제부
이연지(Lee Yeon-Ji) - 가톨릭대학교 서울성모병원 약제부
황은정(Hwang Eun-jeong) - 가톨릭대학교 서울성모병원 약제부
나현오(La Hyen-O) - 가톨릭대학교 의과대학 약리학교실

Abstract

About 70 to 80% of patients who undergo chemotherapy experience chemotherapyinduced nausea and vomiting (CINV), which is one of the most common and important adverse events that affect the quality of life. Palonosetron, one of 5-HT3 receptor antagonists (5-HT3RAs), is used to prevent acute and delayed CINV as the only second-generation drug Between June and September 2009, 103 patients were administered with anticancer drugs containing carboplatin. Among them, patients with cervical, ovarian cancer and non-small cell lung cancer who were treated with carboplatin-paclitaxel or carboplatin-docetaxel, became the subjects of this study. This study was retrospectively performed, and the subjects were classified into two groups, the ramosetron group (R-Group; n=32) and the palonosetron group (P-Group; n=18). The two groups were compared to each other in antiemetic effect and cost. Patients who experienced CINV at least once accounted for 29% and 34% in P-Group and R-Group respectively. 50.9% of P-Group and 45.7% of R-Group took the additional antiemetic drugs. In relation to the cost of antiemetic drugs, P-Group costed a tenth part compared to R-Group.
Also, the cost of adding antiemetics above the drugs included in the regimen, P-Group costed 1/3 less compared to R-Group(p=0.004). In conclusion, palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity. It is expected to be a useful antiemetic in the points of cost-effectiveness and ease of administration. However, this study was conducted on a small number of patients during a short period, thus it was problematic to evaluate the efficacies. A prospective study needs to be performed, excluding other factors that may influence
nausea and vomiting.

키워드

palonosetron, ramosetron, nausea, vomiting, cost-effectiveness

KMID : 0869620100270040392

원문 및 링크아웃 정보

등재저널 정보

주제코드

주제명(Target field)

연구대상(Population)

연구참여(Sample size)

대상성별(Gender)

질병특성(Condition Category)

연구환경(Setting)

연구설계(Study Design)

연구기간(Period)

중재방법(Intervention Type)

중재명칭(Intervention Name)

키워드(Keyword)

유효성결과(Recomendation)

To prevent chemotherapyinduced nausea and vomiting (CINV), palonosetron is as effective as the first-gen-eration of 5-HT3 RAs in frequency of emetogenicity

연구비지원(Fund Source)

근거수준평가(Evidence Hierarchy)

출판년도(Year)

참여저자수(Authors)

대표저자

DOI

KCD코드

ICD 03

건강보험코드

Carboplatin을 포함한 항암제 투여환자에서 유발된 오심, 구토에 대한 palonosetron과 ramosetron의 항구토효과 비교 A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs

Abstract

키워드

Carboplatin을 포함한 항암제 투여환자에서 유발된 오심, 구토에 대한 palonosetron과 ramosetron의 항구토효과 비교
A Comparison between Palonosetron and Ramosetron in Antiemetic Effect in Patients Administered with Carboplatin-containing Anticancer Drugs